Preaching and practice: Evidence-based medicine and the accountability of nephrologists within the health care system. The implications of the findings of the cost-saving potential of subcutaneous versus intravenous epoetin therapy

References 

1. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versuss intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:439–446
   • Abstract
   • Full Text
   • Full-Text PDF (224 KB)
   • CrossRef
2. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure . European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999;14:1–50
   • CrossRef
3. Barrett BJ, Fenton SS, Ferguson B, et al.  Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol. 1999;10(suppl 13):S292–S296
4. United States Renal Data System 1999 Annual Data Report. Am J Kidney Dis. 1999;34(suppl 1):S1–S176
   • Abstract
   • Full-Text PDF (23 KB)
   • CrossRef
5. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619
   • MEDLINE
6. London GM, Pannier B, Guerin AP, et al.  Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759–2767
   • MEDLINE
7. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000;11:335–342
   • MEDLINE